var data={"title":"Potassium phosphate and sodium phosphate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium phosphate and sodium phosphate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6819?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-phosphate-and-sodium-phosphate-drug-information\" class=\"drug drug_general\">see &quot;Potassium phosphate and sodium phosphate: Drug information&quot;</a> and <a href=\"topic.htm?path=potassium-phosphate-and-sodium-phosphate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium phosphate and sodium phosphate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212118\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Av-Phos 250 Neutral;</li>\n      <li>K-Phos Neutral;</li>\n      <li>K-Phos No. 2;</li>\n      <li>Phos-NaK;</li>\n      <li>Phospha 250 Neutral;</li>\n      <li>Phospho-Trin 250 Neutral;</li>\n      <li>Virt-Phos 250 Neutral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032536\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Phosphate Salt</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Potassium Salt</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sodium Salt</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444798\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider the contribution of sodium and potassium when determining the appropriate phosphate replacement. Each mmol of phosphate contains 31 mg elemental phosphorus. Dosage expressed in terms of <b>phosphate</b>.</p>\n    <p style=\"text-indent:0em;margin-right:2em;margin-top:2em;\">\n      <b>Phosphorus: Adequate intake (AI)</b>: Oral: 3.2 mmol/day (IOM 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032554\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=potassium-phosphate-and-sodium-phosphate-drug-information\" class=\"drug drug_general\">see &quot;Potassium phosphate and sodium phosphate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider the contribution of sodium and potassium cations when determining appropriate phosphate replacement. Each mmol of phosphate contains 31 mg elemental phosphorus. Dosage expressed in terms of <b>phosphate/phosphorus</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Phosphorus: Adequate intake (AI) </b>(IOM 1997): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 6 months: 3.2 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 to 12 months: 8.9 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Phosphorus: Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR)</b> (IOM 1997): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 3 years: RDA: 14.8 mmol/day, EAR: 12.3 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4 to 8 years: RDA: 16.1 mmol/day, EAR: 13.1 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 18 years: RDA: 40.3 mmol/day, EAR: 34 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypophosphatemia, maintenance therapy:</b> <b>Note:</b> Dose should be individualized and may vary based on underlying etiology: Infants, Children, and Adolescents: 2 to 3 mmol/kg/day in divided doses, usually at least 4 divided doses (Kliegman 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dietary supplementation:</b> Oral: Av-Phos 250 Neutral, K-Phos Neutral, Phospha 250 Neutral, Virt-Phos 250 Neutral: Children &gt;4 years and Adolescents: 250 mg (1 tablet) 4 times daily (with meals and at bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Phosphate supplement:</b> Tablets (Av-Phos 250 Neutral, K-Phos Neutral, Phospha 250 Neutral, Virt-Phos 250 Neutral): Oral: 250 to 500 mg (1 or 2 tablets) 4 times daily (with meals and at bedtime)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary acidification: </b>K-Phos No. 2: 250 mg (1 tablet) 4 times daily; may increase to 250 mg (1 tablet) every 2 hours; maximum daily dose: 2,000 mg (8 tablets)/<b>24 hours</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution. Contraindicated in patients with severe impairment (&lt;30% of normal function).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212108\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for solution, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Phos-NaK: Dibasic potassium phosphate, monobasic potassium phosphate, dibasic sodium phosphate, and monobasic sodium phosphate per packet (100s) [sugar free; equivalent to elemental phosphorus 250 mg (8 mmol), sodium 160 mg (6.9 mEq), and potassium 280 mg (7.1 mEq) per packet; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Av-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">K-Phos Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">K-Phos No. 2: Potassium acid phosphate 305 mg and sodium acid phosphate 700 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 134 mg (5.8 mEq), and potassium 88 mg (2.3 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Phospha 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Phospho-Trin 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Virt-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212095\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032559\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Administer with a full glass of water; administration with food may reduce the risk of diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral powder: Phos-NaK: Must be diluted in water or juice prior to administration; stir well and use promptly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20164069\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral powder: Store at room temperature; protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light and moisture. Contact of Virt-Phos with moisture may produce surface discoloration or erosion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032537\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment and prevention of hypophosphatemia (Av-Phos 250 Neutral, K-Phos Neutral, Phospha 250 Neutral, Virt-Phos 250 Neutral: FDA approved in ages &gt;4 years and adults); urinary acidification (K-Phos No. 2: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212139\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">K-Phos Neutral may be confused with Neutra-Phos-K [DSC]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212137\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, edema, lower extremity edema, tachycardia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, dizziness, fatigue, headache, paresthesia, seizure, tetany (with large doses of phosphate)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Alkalosis, hyperkalemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, flatulence, nausea, sore throat, stomach pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Decreased urine output</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, limb pain, muscle cramps, ostealgia, paralysis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Acute renal failure </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Increased thirst</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212113\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hyperphosphatemia; infected urinary phosphate stones; severe renal  impairment (&lt;30% of normal)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212098\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Laxative effect: A mild laxative effect may occur within the first few days of therapy; if the laxative effect persists, reduce the dose or discontinue use until diarrhea improves.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenal insufficiency: Use with caution in patients with severe adrenal insufficiency (eg, Addison  disease)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiac disease: Use with caution in patients with cardiac disease, including heart failure (especially patients receiving digoxin) and hypertension. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dehydration: Use with caution in patients with acute dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Edema: Use with caution in patients with peripheral or pulmonary edema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with cirrhosis or severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypernatremia: Use with caution in patients with hypernatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myotonia congenita: Use with caution in patients with myotonia congenita.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Use with caution in patients with acute pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parathyroid disease: Use with caution in patients with hypoparathyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Preeclampsia: Use with caution in pregnant patients with preeclampsia of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal calculi: Patients with renal calculi may pass preformed stones when phosphate therapy is initiated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment or chronic renal disease; use is contraindicated in patient with severe renal impairment (&lt;30% of normal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rickets: Use with caution in patients with rickets; may increase the risk of extraskeletal calcification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tissue breakdown: Use with caution in patients with extensive tissue breakdown (eg, severe burns).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;  Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299926\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212103\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12986&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Urinary Acidifying Agents may decrease the serum concentration of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an iron-containing oral multivitamin as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Potassium Phosphate may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 1 hour before or 2 hours after administration of sucralfate may reduce the significance of the interaction.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212104\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287312\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination. See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032561\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum potassium, sodium, calcium, phosphorus, renal function, reflexes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3458487\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Reference ranges may vary depending on the laboratory. There is a diurnal variation with the nadir at 1100, plateau at 1600, and peak in the early evening (Gaasbeek 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal concentrations (Kleigman 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns (0 to 5 days): 4.8 to 8.2 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: 3.8 to 6.5 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 11 years: 3.7 to 5.6 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">12 to 15 years: 2.9 to 5.4 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;15 years: 2.7 to 4.7 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Hypophosphatemia (Gaasbeek 2005): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate: 1 to 2 mg/dL phosphorus (0.32 to 0.65 mmol/L phosphate)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe: &lt;1 mg/dL phosphorus (&lt;0.32 mmol/L phosphate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45626463\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212112\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;\">Onset of action: Catharsis: Oral: 3 to 6 hours</p>\n    <p style=\"text-indent:0em;\">Absorption: Oral: 1% to 20% </p>\n    <p style=\"text-indent:0em;\">Excretion: Oral forms excreted in feces </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212114\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (K-Phos No 2 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">305-700 mg (100): $106.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (K-Phos-Neutral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">155-852-130 mg (100): $78.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Phospha 250 Neutral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">155-852-130 mg (100): $50.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Phospho-Trin 250 Neutral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">155-852-130 mg (100): $49.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Av-Phos 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Pulaski, TN: AvKare, Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaasbeek A and Meinders AE, &ldquo;Hypophosphatemia: An Update on Its Etiology and Treatment,&rdquo;<i> Am J Med</i>, 2005, 118(10):1094-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-phosphate-and-sodium-phosphate-pediatric-drug-information/abstract-text/16194637/pubmed\" target=\"_blank\" id=\"16194637\">16194637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride, National Academy of Sciences, Washington, DC, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K-Phos Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; June 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K-Phos No. 2 (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Beach Pharmaceuticals; July 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phospha 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Columbus, OH: American Health Packaging; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Virt-Phos 250 Neutral (potassium phosphate/sodium phosphate) [prescribing information]. Tampa, FL: Virtus Pharmaceuticals; May 2015.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12986 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212118\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1032536\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444798\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1032554\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212108\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F212095\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1032559\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F20164069\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1032537\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212139\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212137\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212113\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212098\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299926\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212103\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F212104\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14287312\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1032561\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F3458487\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45626463\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F212112\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F212114\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12986|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-phosphate-and-sodium-phosphate-drug-information\" class=\"drug drug_general\">Potassium phosphate and sodium phosphate: Drug information</a></li><li><a href=\"topic.htm?path=potassium-phosphate-and-sodium-phosphate-patient-drug-information\" class=\"drug drug_patient\">Potassium phosphate and sodium phosphate: Patient drug information</a></li></ul></div></div>","javascript":null}